About US
Contact us
-
New research says UK stroke patients can benefit from new treatmentNew research has found that almost 10,000 UK stroke patients admitted to hospital each year could benefit from a new treatment. Researchers from Newcastle University, Northumbria University, Oxford A2016/12/15
-
Rwanda becomes third country to launch Novartis Access programmeNovartis has announced that Rwanda signed a memorandum of understanding (MoU) and became the third country after Kenya and Ethiopia to launch the Novartis Access programme. With this agreement, the R2016/12/14
-
Sweden’s Pharmalink obtains OMP designation for NefeconThe European Commission (EC) has granted orphan medicinal product (OMP) designation in the European Union (EU) to Swedish-based Pharmalink’s Nefecon (budesonide). Nefecon will be given for patients w2016/12/14
-
Bristol-Myers to pay $19.5 million in Abilify off-label marketing settlementAlmost a decade after settling up Abilify marketing allegations with the U.S. Justice Department, Bristol-Myers Squibb agreed to pay $19.5 million to settle similar claims at the state level. Announc2016/12/13
-
Trump wants to battle high drug prices? Let's work together, hike-fighting senator saysSen. Amy Klobuchar, who early on called for an investigation into Mylan’s EpiPen prices, has a message for President-elect Donald Trump: Let’s bring drug prices down together. In a newop-edfor USA2016/12/13
-
Zetia generics launch sets Merck up for $1.4B hit to 2017 cholesterol salesMerck & Co.'s big-selling cholesterol-fighter Zetia is at the end of its exclusive road. The $2.5 billion sellernow faces its first generic competitor, which threatens not only its own revenue, bu2016/12/12
-
GSK promotes Willemsen as China head, will 'put more energy' into growth prospectsCEO Andrew Witty recently indicatedthat GlaxoSmithKline’s China business has "fundamentally"returned to growth years after being embroiled in a bribery scandal. Now, the company has tapped a new China2016/12/12
-
Analysts to Wall Street: Don't celebrate yet. The drug-pricing brouhaha is far from overWhen presidential candidate Hillary Clinton blasted Martin Shkreli on Twitter for hiking the price of an old drug called Daraprim by 5,000% in September 2015, biotech stocks plummeted. Clinton tweeted2016/12/9
-
What puts a new drug launch in line for victory? Ask Gilead, Biogen and J&JDrugmakers spend billions on R&D every year, hoping to createa drug that can throw a commercial punch. It’s never perfectly clear which projects will reach the market, much less deliver big sales,2016/12/9
-
Once-spurned cancer drugs win NICE's favor with—no surprise—'sensible pricing'England’s cost-effectiveness watchdogs are a tough audience, and they've often angered cancer drugmakers when meds were turned away. Recently, however, a steady stream of oncology meds have made it th2016/12/8